Sponsor study identifier
Secondary identifiers
NIH
interventional
420
1 country
2
Study Start
September 5, 2023
Actual (reported)Primary Completion
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 5, 2023
Actual (reported)September 5, 2023
Actual (reported)September 13, 2023
Actual (reported)June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Days of Drug Use
Number of days of drug use as measured by self-reported days of use and biochemically verified use via drug screen.
Baseline through 52 weeks.
Days of Tobacco Use
Number of days of tobacco use as measured by self-reported days of use and biochemically verified use via expired carbon monoxide.
Baseline through 52 weeks.
Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901, United States
University of Utah
Salt Lake City, Utah, 84108, United States
Nina Cooperman, PsyD
Rutgers Robert Wood Johnson Medical School
First Submitted
September 5, 2023
First Posted
September 13, 2023
Study Start
September 5, 2023
Actual (reported)Primary Completion
June 2028
EstimatedNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
Eight group support group sessions and and nicotine replacement therapy.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 17, 2026
Record last verified: 2026-07
All participant individual data will be available after de-identification.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: